References
- Mirbolouk M, Charkhchi P, Kianoush S, Uddin SMI, Orimoloye OA, Jaber
R, Bhatnagar A, Benjamin EJ, Hall ME, DeFilippis AP, Maziak W, Nasir
K, Blaha MJ. Prevalence and Distribution of E-Cigarette Use Among U.S.
Adults: Behavioral Risk Factor Surveillance System, 2016. Ann Intern
Med. 2018;169(7):429-438.
- Patrick ME, Schulenberg JE, Miech RA, Johnston LD, O’Malley PM,
Bachman JG. Monitoring the Future Panel Study annual report: National
data on substance use among adults ages 19 to 60, 1976-2021.
Monitoring the Future Monograph Series. 2022.
- Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis
in the era of precision medicine. Front Pharmacol. 2020;10:1662.
- Grossoehme DH, Cotton S, McPhail G. Use and sanctification of
complementary and alternative medicine by parents of children with
cystic fibrosis. J Health Care Chaplain. 2013;19(1):22-32.
- Giangioppo S, Kalaci O, Radhakrishnan A, et al. Complementary and
alternative medicine use in children with cystic fibrosis. Complement
Ther Clin Pract. 2016;25:68-74.
- Stephen MJ, Chowdhury J, Tejada LA, Zanni R, Hadjiliadis D. Use of
medical marijuana in cystic fibrosis patients. BMC Complement Med
Ther. 2020;20:1-5.
- Hamberger ES, Halpern-Felsher B. Concern over tobacco and marijuana
perceptions and use among adolescents and young adults with cystic
fibrosis. Addict Behav. 2023;142:107669.
- Sholler DJ, Schoene L, Spindle TR. Therapeutic Efficacy of Cannabidiol
(CBD): A Review of the Evidence from Clinical Trials and Human
Laboratory Studies. Curr Addict Rep. 2020;7(3):405-412.
- Muirhead CA, Palmrose W, Condren M, Rotolo SM, Pettit RS, Gill M, Phan
H. A clinician survey of use assessment, documentation, and education
about cannabis in persons with cystic fibrosis. Pediatr Pulmonol.
2021;56(9):2879-2887.
- Bhat TA, Kalathil SG, Goniewicz ML, Hutson A, Thanavala Y. Not all
vaping is the same: differential pulmonary effects of vaping
cannabidiol versus nicotine. Thorax. 2023;78(9):922-932.
- Davenport S. Price and product variation in Washington’s recreational
cannabis market. Int J Drug Policy. 2021;91:102547.
- Friese B, Slater MD, Annechino R, Battle RS. Teen Use of Marijuana
Edibles: A Focus Group Study of an Emerging Issue. J Prim Prev.
2016;37(3):303-309.
- Foster BC, Abramovici H, Harris CS. Cannabis and cannabinoids:
kinetics and interactions. Am J Med. 2019;132:1266-1270.
- Schier JG, Meiman JG, Layden J, Mikosz CA, VanFrank B, King BA,
Salvatore PP, Weissman DN, Thomas J, Melstrom PC, Baldwin GT, Parker
EM, Courtney-Long EA, Krishnasamy VP, Pickens CM, Evans ME, Tsay SV,
Powell KM, Kiernan EA, Marynak KL, Adjemian J, Holton K, Armour BS,
England LJ, Briss PA, Houry D, Hacker KA, Reagan-Steiner S, Zaki S,
Meaney-Delman D; CDC 2019 Lung Injury Response Group. Severe Pulmonary
Disease Associated with Electronic-Cigarette-Product Use - Interim
Guidance. MMWR Morb Mortal Wkly Rep. 2019;68(36):787-790.
- Baker E, Harris WT, Rowe SM, Rutland SB, Oates GR. Tobacco smoke
exposure limits the therapeutic benefit of tezacaftor/ivacaftor in
pediatric patients with cystic fibrosis. J Cyst Fibros.
2021;20(4):612-617.
- Havermans T, Duff AJ. Changing landscape: psychological care in the
era of cystic fibrosis transmembrane conductance regulator modulators.
Curr Opin Pulm Med. 2020;26(6):696-701.
- Guta MT, Tekalign T, Awoke N, Fite RO, Dendir G, Lenjebo TL. Global
burden of anxiety and depression among cystic fibrosis patients:
Systematic review and meta-analysis. Int J Chronic Dis. 2021;2021.
- Stolerman IP, Jarvis M. The scientific case that nicotine is
addictive. Psychopharmacology. 1995;117:2-10.
- Hines LA, Freeman TP, Gage SH, Zammit S, Hickman M, Cannon M, Munafo
M, MacLeod J, Heron J. Association of High-Potency Cannabis Use With
Mental Health and Substance Use in Adolescence. JAMA Psychiatry.
2020;77(10):1044.
- Keyte R, Egan H, Nash EF, Regan A, Jackson C, Mantzios M. An
exploration into experiences and attitudes regarding risky health
behaviors in an adult cystic fibrosis population. Psychol Health Med.
2020;25(8):1013-1019.